BriaCell’s Bria-IMT Shows Strong Survival & Benefit in Advanced Breast Cancer

On Monday, BriaCell Therapeutics Corp. (NASDAQ:BCTX) announced robust overall survival and clinical benefit data from its Bria-IMT and Bria-OTS studies in metastatic breast cancer/MBC at the 2025 ASCO Annual Meeting.

BriaCell's Bria-IMT Shows Strong Survival & Benefit in Advanced Breast Cancer

A patient receiving a personalized immunotherapy treatment.

In a Phase 2 study, BriaCell’s cancer drug Bria-IMT, combined with another treatment, showed strong results in 54 patients with advanced breast cancer who had already tried many other therapies. The drug was effective across all types of breast cancer, with 55% of patients showing a clinical benefit. Notably, 100% of HER2+ patients responded positively. Patients receiving a specific Phase 3 formulation of Bria-IMT lived significantly longer, with a median of 13.9 months compared to 6.93 months for another version of the drug.

For patients treated since 2022 with this formulation, the median survival reached 17.3 months, which is better than similar historical treatments. The drug was also well-tolerated, with very few patients stopping treatment due to side effects. These promising results are now being further tested in a larger Phase 3 study. Additionally, BriaCell is testing another drug, Bria-OTS, in a Phase 1/2 study for advanced breast cancer.

BriaCell Therapeutics Corp. (NASDAQ:BCTX) is a clinical-stage immuno-oncology company that develops targeted immunotherapies to transform cancer care.

While we acknowledge the potential of BCTX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BCTX and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.